- CureVac N.V. CVAC dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc GSK.
- The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.
- A preclinical study of CV2CoV in cynomolgus macaques, published in Nature in November 2021, demonstrated rapid induction of higher antibody titers, better induction of immune memory, and more robust protective efficacy of CV2CoV compared to CureVac’s first-generation vaccine candidate, CVnCoV.
- Related: CureVac Outlines Upcoming Catalysts For Vaccine Programs.
- The same study demonstrated comparable neutralizing antibody titers in vaccinated animals with either 12µg of CV2CoV or a 30µg standard dose of a licensed mRNA COVID-19 vaccine.
- The Phase 1 dose-escalation study will enroll up to 210 healthy adults to evaluate the safety, reactogenicity, and immunogenicity of CV2CoV in the dose range of 2 to 20µg.
- Data results from the Phase 1 study are expected in 2H of 2022.
- Price Action: CVAC shares are down 0.05% at $19.19, GSK stock is up 0.64% at $43.57 during the market session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.